Phase 3 Trial Demonstrates Safety and Efficacy of Epithelium-On Corneal Cross-Linking for Keratoconus Treatment
核心洞察
A Phase 3 clinical trial showed epithelium-on corneal cross-linking (搜索) achieved a full 1-diopter difference between treatment and sham groups, with the treatment group demonstrating half-diopter corneal flattening at 12 months.
The innovative procedure uses specialized oxygen-enriched goggles maintaining over 90% oxygen concentration to enable efficient aerobic cross-linking while preserving the epithelial layer.
The safety profile was exceptional with no serious adverse events reported, eliminating risks associated with traditional epithelium-off approaches including infection, delayed healing, and scarring.
A groundbreaking Phase 3 clinical trial has demonstrated the safety and efficacy of epithelium-on corneal cross-linking (搜索) (CXL) for keratoconus (搜索) treatment, potentially revolutionizing how clinicians approach this progressive eye condition. The study, presented at the 2025 American Academy of Ophthalmology meeting in Orlando, Florida, by Dr. Ken Beckman, a corneal specialist and clinical assistant professor at The Ohio State University, addresses critical limitations of traditional cross-linking methods.
Novel Oxygen Delivery System Enables Effective Treatment
The breakthrough centers on solving a fundamental challenge in corneal cross-linking (搜索): maintaining adequate oxygen concentration during treatment. According to Dr. Beckman, efficient aerobic cross-linking requires three essential components: riboflavin, light, and oxygen. "The minute the light turns on, oxygen would ordinarily be depleted down to almost zero," Beckman explained.
The innovative solution involves specialized goggles worn by patients during the procedure. Within the goggle chamber, oxygen is pumped to maintain concentrations greater than 90%, ensuring sufficient oxygen levels within the corneal stroma (搜索) throughout the entire treatment process. This high-concentration oxygen environment enables aerobic, efficient cross-linking while preserving the epithelial layer.
Phase 3 Trial Results Show Significant Efficacy
The multicenter Phase 3 trial employed a 2-to-1 randomization ratio of treatment to sham groups. The primary outcome measure focused on achieving a 1-diopter difference in K max, the steepest K reading on pentacam topography, between the two groups.
After 12 months of follow-up, the results were compelling. The treatment group demonstrated a half-diopter flattening of the cornea, while the sham group showed a half-diopter steepening. "We did find the full 1-diopter delta between the 2 groups," Beckman reported, meeting the trial's primary efficacy endpoint.
Superior Safety Profile Eliminates Traditional Risks
The safety profile of epithelium-on CXL proved exceptional compared to conventional epithelium-off approaches. Traditional epi-off cross-linking carries multiple risks including patient discomfort, infection due to epithelial defects, contact lens-related complications, delayed wound healing, scarring, haze, and delayed visual recovery.
In contrast, the epithelium-on procedure showed no serious adverse events. "All of the adverse events were minor. They included things like irritation and SPK, but nothing serious. So it was very well tolerated," Beckman noted. This dramatic improvement in safety profile stems from preserving the epithelial layer, which serves as a natural barrier against infection and other complications.
Expanded Treatment Eligibility and Clinical Impact
The procedure's enhanced safety profile may significantly expand treatment eligibility for keratoconus (搜索) patients. Beckman suggested the technique could lower the threshold for treating patients, particularly those with thinner corneas or those at risk of surface disease. The preservation of the epithelium represents a key advantage that significantly reduces procedural risks.
The study's implications extend beyond safety improvements. By maintaining oxygen concentration while preserving the epithelial layer, this innovative cross-linking method offers clinicians a safer, more accessible approach to managing keratoconus (搜索). The results suggest that practitioners can consider treating a broader range of patients with increased confidence in both the procedure's safety and effectiveness.
This advancement in keratoconus (搜索) treatment represents a significant step forward in corneal care, potentially making cross-linking therapy available to patients who previously may not have been candidates due to safety concerns or anatomical limitations.